Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis

This study has been completed.
Information provided by:
Chinese University of Hong Kong Identifier:
First received: July 29, 2005
Last updated: July 31, 2015
Last verified: May 2008
The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.

Condition Intervention Phase
Lupus Nephritis
Lupus Erythematosus, Systemic
Drug: tacrolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis

Resource links provided by NLM:

Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • Change in 24-hour urinary protein excretion

Secondary Outcome Measures:
  • Development of renal flare
  • Development of non-renal flare

Estimated Enrollment: 20
Study Start Date: January 2004
Study Completion Date: February 2008
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Detailed Description:
Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). The treatment of membranous (type V) lupus nephritis, a subset that carries a high morbidity, remains unsatisfactory. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cells, for example, tacrolimus, may be effective in the treatment of primary membranous nephropathy. The investigators plan to conduct an open-label single-arm study of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy secondary to SLE. Twenty patients with biopsy-proven membranous nephropathy secondary to SLE will be recruited. They will be treated with oral prednisolone and tacrolimus for 6 months, followed by 6 months of maintenance steroids alone. Proteinuria, renal function, clinical and serologic lupus activity will be monitored. Complete remission is defined as 24-hour urinary protein excretion to less than 0.5 gm/day. This study will explore the potential role of tacrolimus in the treatment of membranous lupus nephritis, which is usually resistant to conventional therapy.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fulfill the revised American College of Rheumatology criteria for SLE
  • Have biopsy-proven membranous nephropathy secondary to SLE
  • Nephrotic syndrome with proteinuria (> 3 g/day) and serum albumin < 30 g/dl, with or without active urinary sediments despite steroid therapy (with or without cytotoxic agents)
  • Age over 18 with informed consent
  • Female patients of child-bearing age and male patients who agree to maintain effective birth control practice during the study

Exclusion Criteria:

  • Patient with abnormal liver function tests
  • Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
  • Patient who is diabetic
  • Patient who is receiving non-steroidal anti-inflammatory drugs (NSAIDs) or other agents known to influence urinary protein excretion
  • Patient is allergic or intolerant to macrolide antibiotics or tacrolimus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00125307

Hong Kong
Department of Medicine & Therapeutics, Prince of Wales Hospital
Shatin, Hong Kong
Sponsors and Collaborators
Chinese University of Hong Kong
Principal Investigator: Cheuk-Chun Szeto, MD Chinese University of Hong Kong
  More Information Identifier: NCT00125307     History of Changes
Other Study ID Numbers: CRE-2004.229-T
Study First Received: July 29, 2005
Last Updated: July 31, 2015

Keywords provided by Chinese University of Hong Kong:
immunosuppressive therapy
type V (membranous) lupus nephritis

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Lupus Nephritis
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Kidney Diseases
Urologic Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017